Picard Medical, Inc. (PMI)

Publicly reported company facts and saved market data for Picard Medical, Inc. (PMI), with sources and as-of times. Saved data is not a live quote.

Company profile

Picard Medical, Inc. is the parent company of SynCardia Systems, LLC ('SynCardia'), the Tucson, Arizona-based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart ('STAH'), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the STAH is the most widely used and extensively studied artificial heart in the world.

Company facts

Industry: Surgical & Medical Instruments & Apparatus
Market cap: $19.5M · as of 2026-10-30
Incorporated in: United States
Exchange: NYSE American

FennEdge notes

Sessions where PMI appeared in the Small-Cap Daily, newest first: opening gap, day change and the SEC filing or halt stored by the close. Facts with source links.

2026-10-16 #6 top gapper · gap +22.10% · closed +27.50% No SEC filing or news found by the close

All Small-Cap Daily editions

Saved quote

Saved snapshot, not a real-time quote. Check the market time before relying on it.

Last reported price: $8.29
Reported change: +2.22%
Reported volume: 56,340
Latest market time: 2026-10-30 19:30 ET

Float and shares outstanding

PMI float references and SEC-reported shares outstanding
Measure	Shares	As of	Source and basis
Float	1,290,692	2026-08-19	Reported by a single source; not cross-checked.
Shares outstanding (O/S)	2,338,634	2026-08-18	SEC 10-Q filing · filed 2026-08-19

Dates are measurement dates, not the time FennEdge retrieved the data. Float references are listed separately; they are not averaged or adjusted for later splits or share issuances.

Dilution timeline

As of 2026-10-20T23:55:06.138975+00:00

2026-10-06 · 8-K · Current report filed
2026-07-22 · 8-K · Current report filed
2026-06-01 · 424B3 · Prospectus filed
2026-05-29 · EFFECT · Effectiveness notice filed
2026-05-20 · S-1 · Registration statement filed
2026-05-06 · 424B4 · Prospectus filed
2026-05-05 · 8-K · Current report filed
2026-05-04 · EFFECT · Effectiveness notice filed
2026-05-01 · S-1/A · Registration statement filed
2026-04-27 · S-1 · Registration statement filed
2026-04-13 · 8-K · Current report filed
2026-02-10 · 424B3 · Prospectus filed
2026-02-06 · EFFECT · Effectiveness notice filed
2026-02-04 · S-1/A · Registration statement filed
2026-01-12 · S-1 · Registration statement filed

Parsed share counts, prices and warrant terms require Plus or above. Explore plans

Research this company

FennEdge organizes SEC filings and reported market data. Sign in for additional research and your private trading context.